This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Widmer, F.
Right arrow Articles by Sorrell, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Widmer, F.
Right arrow Articles by Sorrell, T. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 414-421, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.414-421.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Hexadecylphosphocholine (Miltefosine) Has Broad-Spectrum Fungicidal Activity and Is Efficacious in a Mouse Model of Cryptococcosis

Fred Widmer,1 Lesley C. Wright,1 Daniel Obando,1 Rosemary Handke,3 Ranjini Ganendren,1 David H. Ellis,3 and Tania C. Sorrell1,2*

Centre for Infectious Diseases and Microbiology, University of Sydney at Westmead, and Department of Infectious Diseases, ICPMR Building, Westmead Hospital, Westmead, NSW 2145,1 Centre for Clinical Research Excellence in Infections & Bioethics in Haematological Malignancies, University of Sydney, Sydney, NSW 2006,2 Women's and Children's Hospital, North Adelaide, South Australia 5006, Australia3

Received 18 May 2005/ Returned for modification 30 July 2005/ Accepted 31 October 2005

The alkyl phosphocholine drug miltefosine is structurally similar to natural substrates of the fungal virulence determinant phospholipase B1 (PLB1), which is a potential drug target. We determined the MICs of miltefosine against key fungal pathogens, correlated antifungal activity with inhibition of the PLB1 activities (PLB, lysophospholipase [LPL], and lysophospholipase-transacylase [LPTA]), and investigated its efficacy in a mouse model of disseminated cryptococcosis. Miltefosine inhibited secreted cryptococcal LPTA activity by 35% at the subhemolytic concentration of 25 µM (10.2 µg/ml) and was inactive against mammalian pancreatic phospholipase A2 (PLA2). At 250 µM, cytosolic PLB, LPL, and LPTA activities were inhibited by 25%, 51%, and 77%, respectively. The MICs at which 90% of isolates were inhibited (MIC90s) against Candida albicans, Candida glabrata, Candida krusei, Cryptococcus neoformans, Cryptococcus gattii, Aspergillus fumigatus, Fusarium solani, Scedosporium prolificans, and Scedosporium apiospermum were 2 to 4 µg/ml. The MICs of miltefosine against Candida tropicalis (n = 8) were 2 to 4 µg/ml, those against Aspergillus terreus and Candida parapsilosis were 8 µg/ml (MIC90), and those against Aspergillus flavus (n = 8) were 2 to 16 µg/ml. Miltefosine was fungicidal for C. neoformans, with rates of killing of 2 log units within 4 h at 7.0 µM (2.8 µg/ml). Miltefosine given orally to mice on days 1 to 5 after intravenous infection with C. neoformans delayed the development of illness and mortality and significantly reduced the brain cryptococcal burden. We conclude that miltefosine has broad-spectrum antifungal activity and is active in vivo in a mouse model of disseminated cryptococcosis. The relatively small inhibitory effect on PLB1 enzyme activities at concentrations exceeding the MIC by 2 to 20 times suggests that PLB1 inhibition is not the only mechanism of the antifungal effect.

* Corresponding author. Mailing address: Centre for Infectious Diseases and Microbiology, Level 3, ICPMR Building, Westmead Hospital, Westmead, NSW 2145, Australia. Phone: 612-98456012. Fax: 612-98915317. E-mail: tanias{at}icpmr.wsahs.nsw.gov.au.

Antimicrobial Agents and Chemotherapy, February 2006, p. 414-421, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.414-421.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Walochnik, J., Obwaller, A., Gruber, F., Mildner, M., Tschachler, E., Suchomel, M., Duchene, M., Auer, H. (2009). Anti-Acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent. J Antimicrob Chemother 64: 539-545 [Abstract] [Full Text]  
  • Kim, J.-H., Jung, S.-Y., Lee, Y.-J., Song, K.-J., Kwon, D., Kim, K., Park, S., Im, K.-I., Shin, H.-J. (2008). Effect of Therapeutic Chemical Agents In Vitro and on Experimental Meningoencephalitis Due to Naegleria fowleri. Antimicrob. Agents Chemother. 52: 4010-4016 [Abstract] [Full Text]  
  • Tong, Z., Widmer, F., Sorrell, T. C., Guse, Z., Jolliffe, K. A., Halliday, C., Lee, O. C., Kong, F., Wright, L. C., Chen, S. C. A. (2007). In Vitro Activities of Miltefosine and Two Novel Antifungal Biscationic Salts against a Panel of 77 Dermatophytes. Antimicrob. Agents Chemother. 51: 2219-2222 [Abstract] [Full Text]  
  • Llull, D., Rivas, L., Garcia, E. (2007). In Vitro Bactericidal Activity of the Antiprotozoal Drug Miltefosine against Streptococcus pneumoniae and Other Pathogenic Streptococci. Antimicrob. Agents Chemother. 51: 1844-1848 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»